CN1778355A - 一种治疗糖尿病的中药组合物及其制剂和用途 - Google Patents
一种治疗糖尿病的中药组合物及其制剂和用途 Download PDFInfo
- Publication number
- CN1778355A CN1778355A CN 200410091137 CN200410091137A CN1778355A CN 1778355 A CN1778355 A CN 1778355A CN 200410091137 CN200410091137 CN 200410091137 CN 200410091137 A CN200410091137 A CN 200410091137A CN 1778355 A CN1778355 A CN 1778355A
- Authority
- CN
- China
- Prior art keywords
- radix paeoniae
- paeoniae rubra
- total glycosides
- chinese medicine
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims description 30
- 229930182470 glycoside Natural products 0.000 claims abstract description 156
- 150000002338 glycosides Chemical class 0.000 claims abstract description 153
- 238000000034 method Methods 0.000 claims abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 52
- 239000000284 extract Substances 0.000 claims description 51
- 239000011347 resin Substances 0.000 claims description 30
- 229920005989 resin Polymers 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000012567 medical material Substances 0.000 claims description 25
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 25
- 229930182490 saponin Natural products 0.000 claims description 25
- 150000007949 saponins Chemical class 0.000 claims description 25
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 239000012535 impurity Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 7
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000005487 catechin Nutrition 0.000 claims description 3
- 229950001002 cianidanol Drugs 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 229940074391 gallic acid Drugs 0.000 claims description 3
- 235000004515 gallic acid Nutrition 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 229920000296 Glucogallin Polymers 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 229940100691 oral capsule Drugs 0.000 claims 1
- 229940096978 oral tablet Drugs 0.000 claims 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract description 22
- 241000736199 Paeonia Species 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 description 68
- 239000008280 blood Substances 0.000 description 68
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 39
- 239000008103 glucose Substances 0.000 description 39
- 241000700159 Rattus Species 0.000 description 28
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 241001106477 Paeoniaceae Species 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 206010022489 Insulin Resistance Diseases 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 17
- 239000013641 positive control Substances 0.000 description 17
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 14
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 14
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 229960001052 streptozocin Drugs 0.000 description 13
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 235000001727 glucose Nutrition 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- -1 lactone glycoside Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- JGWYMAUEOSXSLU-UHFFFAOYSA-N Lactiflorin Natural products CC12CC(=O)C3CC(COC(=O)c4ccccc4)(C3O1)C25OC6OC(CO)C(O)C(O)C6O5 JGWYMAUEOSXSLU-UHFFFAOYSA-N 0.000 description 2
- 244000236658 Paeonia lactiflora Species 0.000 description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- AGRYIZUKIKYUFX-DNITZUGTSA-N lactiflorin Chemical compound C([C@@]12[C@]34C[C@H]2C(=O)C[C@H]1O[C@@]3(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O4)C)OC(=O)C1=CC=CC=C1 AGRYIZUKIKYUFX-DNITZUGTSA-N 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000009835 oxypaeoniflora Substances 0.000 description 2
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 2
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005353 urine analysis Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NLSMPWTZYGSAEU-CYUNEVMDSA-N (2s,3r,4s,5s,6r)-2-[7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromenylium-5-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 NLSMPWTZYGSAEU-CYUNEVMDSA-N 0.000 description 1
- QJYNZEYHSMRWBK-XCEMISLISA-N 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose Natural products O=C(OC[C@H]1[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)O1)c1cc(O)c(O)c(O)c1 QJYNZEYHSMRWBK-XCEMISLISA-N 0.000 description 1
- QJYNZEYHSMRWBK-NIKIMHBISA-N 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose Chemical compound OC1=C(O)C(O)=CC(C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 QJYNZEYHSMRWBK-NIKIMHBISA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- QMNAQPMXDMLOLD-UHFFFAOYSA-N 6-methyl-4-oxo-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfonamide Chemical compound S1C(C)CC(=O)C2=C1SC(S(N)(=O)=O)=C2 QMNAQPMXDMLOLD-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QQUHMASGPODSIW-UHFFFAOYSA-N Albiflorin Natural products C=1C=CC=CC=1C(=O)OCC12C(=O)OC3(C)CC(O)C1CC32OC1OC(CO)C(O)C(O)C1O QQUHMASGPODSIW-UHFFFAOYSA-N 0.000 description 1
- IRLNKOAURQPXIQ-WWWUCTDISA-N Apiopaeonoside Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc(OC)cc1 IRLNKOAURQPXIQ-WWWUCTDISA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- KLFIUQCKSSAFFU-QHOIGUMUSA-N Galloylpaeoniflorin Natural products O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@]23[C@]4(COC(=O)c5ccccc5)[C@@H]5O[C@@]2(C)C[C@@](O)(O5)[C@@H]4C3)O1)c1cc(O)c(O)c(O)c1 KLFIUQCKSSAFFU-QHOIGUMUSA-N 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- IDZZECHGWAZTIB-NYBIBFQCSA-N Paeonolide Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@@H](O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-NYBIBFQCSA-N 0.000 description 1
- IDZZECHGWAZTIB-WPQJODJHSA-N Paeonolide Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@H](O)[C@@H](O)CO3)O2)cc(OC)cc1 IDZZECHGWAZTIB-WPQJODJHSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001593750 Turcica Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- IDZZECHGWAZTIB-UHFFFAOYSA-N affinoside Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-UHFFFAOYSA-N 0.000 description 1
- QQUHMASGPODSIW-ICECTASOSA-N albiflorin Chemical compound O([C@@]12C[C@H]3[C@H](O)C[C@@]1(OC(=O)[C@]32COC(=O)C=1C=CC=CC=1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QQUHMASGPODSIW-ICECTASOSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- VQKFNUFAXTZWDK-UHFFFAOYSA-N alpha-methylfuran Natural products CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 239000010828 animal waste Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000011697 diabetes animal model Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- KLFIUQCKSSAFFU-ANNBSXMPSA-N galloylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=C(O)C(O)=C(O)C=2)O1)O)C)OC(=O)C1=CC=CC=C1 KLFIUQCKSSAFFU-ANNBSXMPSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011657 insulin resistance animal model Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229930194807 paeonin Natural products 0.000 description 1
- 229930183616 paeoniside Natural products 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960001753 phenformin hydrochloride Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
化合物 | 中文名 | 英文名 |
1234 | 芍药苷儿茶素没食子酸五没食子酰基葡萄糖 | PaeoniflorinCatechinGallic acidPentagalloyl β-D-glucose |
编号 | 芍药苷量(ug) | 峰面积 |
1 | 0.4592 | 565516 |
2 | 0.9184 | 1171490 |
3 | 1.3776 | 1783885 |
4 | 1.8368 | 2344300 |
5 | 2.2960 | 2895713 |
组别 | 剂量mg/kg | n | 血糖(mmol/L) | |||
0天 | 3天 | 7天 | 12天 | |||
正常对照组模型对照组阳性对照组赤芍总苷小剂量组赤芍总苷中剂量组赤芍总苷大剂量组 | 蒸馏水蒸馏水1004080160 | 101010101010 | 3.47±0.5218.56±4.25△△△18.48±4.3018.55±5.0118.44±5.0018.50±4.93 | 3.53±0.5118.96±4.86△△△15.70±2.40*15.85±2.34*15.43±2.07*15.25±2.12* | 3.34±0.5818.78±4.57△△△14.77±2.10**15.27±2.54*15.20±2.28*14.70±2.30* | 3.36±0.5020.04±4.70△△△14.79±2.92**15.22±2.46*14.88±2.56**13.52±2.01** |
组别 | 剂量mg/kg | n | 血糖(mmol/L) | |||
0天 | 3天 | 7天 | 12天 | |||
正常对照组模型对照组阳性对照组 | 蒸馏水蒸馏水100 | 101010 | 3.81±0.3318.95±4.51△△△18.67±4.37 | 4.00±0.6018.90±4.60△△△15.64±2.68* | 4.04±0.5918.05±3.20△△△14.42±2.77** | 3.83±0.5417.81±3.58△△△13.82±2.04** |
赤芍总苷小剂量组赤芍总苷中剂量组赤芍总苷大剂量组 | 50100200 | 101010 | 18.48±4.3318.50±4.1918.45±4.27 | 15.24±3.99*14.90±3.58*14.76±2.84* | 14.78±2.54*14.55±2.56**14.09±2.74** | 14.53±2.81*14.06±1.80**12.63±2.10*** |
组别 | 剂量 | n | 血糖(mmol/L) |
mg/kg | 0天 | 3天 | 7天 | 12天 | ||
正常对照组模型对照组阳性对照组赤芍总苷小剂量组赤芍总苷中剂量组赤芍总苷大剂量组 | 蒸馏水蒸馏水1004080160 | 101010101010 | 3.18±0.5321.03±3.80△△△20.59±3.7920.83±3.8020.87±3.8020.90±3.80 | 3.58±0.5621.73±4.22△△△18.71±3.02*18.75±2.34*18.36±2.89*17.17±2.70** | 3.39±0.5720.52±3.90△△△16.74±2.98*17.22±3.30*17.22±2.34*14.98±3.57** | 3.46±0.4821.07±4.44△△△15.62±3.67**16.22±3.00*15.85±2.48**14.41±2.80*** |
组别 | 剂量mg/kg | n | 血糖(mmol/L) | |||
0天 | 3天 | 7天 | 12天 | |||
正常对照组模型对照组阳性对照组赤芍总苷小剂量组赤芍总苷中剂量组赤芍总苷大剂量组 | 蒸馏水蒸馏水10050100200 | 101010101010 | 4.58±0.8020.73±3.91△△△20.70±3.9221.16±3.6420.09±3.8320.03±3.98 | 3.90±0.9420.15±3.32△△△13.18±5.35***17.64±3.3415.93±4.55*15.24±4.92** | 4.11±0.8919.63±5.08△△△14.35±2.75**15.85±3.67*14.86±3.95*13.09±3.44** | 4.64±0.8118.27±2.65△△△15.20±2.87*15.00±3.60*14.80±2.52**13.30±2.91*** |
组别 | 剂量mg/kg | n | 体重(g) | ||||
0w | 1w | 2w | 3w | 4w | |||
正常对照组模型对照组阳性对照组赤芍总苷 | 10040 | 12121212 | 239±13236±17239±12240±9 | 278±13289±18279±14284±9 | 306±14320±18△308±15306±10* | 327±15331±17326±12324±12 | 346±15354±17351±16353±11 |
小剂量组赤芍总苷中剂量组赤芍总苷大剂量组 | 80160 | 1212 | 242±16240±12 | 286±15279±15 | 308±15307±12 | 322±15324±13 | 351±15351±14 |
组别 | 剂量mg/kg | n | 空腹血糖(mmol/L) | 血清胰岛素(μIU/mL) |
正常对照组模型对照组阳性对照组赤芍总苷小剂量组赤芍总苷中剂量组赤芍总苷大剂量组 | 1004080160 | 121212121212 | 2.3±0.24.6±0.3△△△2.8±0.3***4.1±0.4*2.9±0.2***2.9±0.2*** | 27.26±3.6331.20±6.72△25.21±2.26**29.71±6.9528.11±8.1226.53±3.74* |
组别 | 剂量mg/kg | n | T-CHO(mmol/L) | TG(mmol/L) | LDL(mmol/L) |
正常对照组模型对照组阳性对照组赤芍总苷小剂量组赤芍总苷中剂量组赤芍总苷大剂量组 | 1004080160 | 121212121212 | 1.46±0.293.93±0.71△△△2.56±0.41**2.55±0.59**2.23±0.39***2.53±0.45** | 0.42±0.140.82±0.22△△△0.65±0.13*0.59±0.19*0.62±0.10**0.62±0.12* | 1.29±0.352.15±0.40△△△1.72±0.22**1.68±0.43*1.58±0.28***1.68±0.29** |
组别 | 剂量mg/kg | n | 血糖(mmol/L) | K值 | ||||
3min | 6min | 9min | 12min | 15min | ||||
正常对照组模型对照组阳性对照组赤芍总苷小剂量赤芍总苷中剂量赤芍总苷大剂量 | 1004080160 | 121212121212 | 13.3±2.213.5±1.813.0±3.813.0±1.812.9±1.913.4±1.6 | 10.9±1.811.3±1.911.0±3.311.3±1.811.1±1.911.5±1.5 | 8.8±1.49.9±1.49.2±2.89.4±1.79.7±1.69.6±1.4 | 7.2±1.09.0±1.5△△7.8±2.88.2±1.48.1±1.28.2±1.2 | 5.1±0.78.3±1.2△△△6.0±2.36.5±1.2**6.3±1.0***6.3±1.3*** | 0.67±0.180.43±0.11△△△0.57±0.13**0.54±0.13*0.55±0.14*0.58±0.15** |
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100911379A CN100411653C (zh) | 2004-11-19 | 2004-11-19 | 一种治疗糖尿病的中药组合物及其制剂和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100911379A CN100411653C (zh) | 2004-11-19 | 2004-11-19 | 一种治疗糖尿病的中药组合物及其制剂和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1778355A true CN1778355A (zh) | 2006-05-31 |
CN100411653C CN100411653C (zh) | 2008-08-20 |
Family
ID=36768892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100911379A Active CN100411653C (zh) | 2004-11-19 | 2004-11-19 | 一种治疗糖尿病的中药组合物及其制剂和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100411653C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102973676A (zh) * | 2012-12-14 | 2013-03-20 | 中国中医科学院西苑医院 | 一种防治心血管疾病的药物及其制备方法 |
CN103263486A (zh) * | 2013-06-13 | 2013-08-28 | 陈曦 | 一种具有降糖活性的赤芍提取物的应用 |
CN104337884A (zh) * | 2013-08-06 | 2015-02-11 | 颜明 | 一种预防和/或治疗糖尿病及其并发症的药物组合物 |
CN105232641A (zh) * | 2015-10-21 | 2016-01-13 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 赤芍总苷在制备预防或治疗微波辐射致神经细胞损伤药物中的用途、药物组合物及食品 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1054053C (zh) * | 1995-03-11 | 2000-07-05 | 朱立群 | 降糖药及其制备方法 |
CN1075727C (zh) * | 1997-03-12 | 2001-12-05 | 孙松 | 治疗神经病变的胶囊及其生产方法 |
CN1148208C (zh) * | 2001-02-26 | 2004-05-05 | 吕玉娥 | 治疗糖尿病的药物及其制法 |
CN1199650C (zh) * | 2003-04-07 | 2005-05-04 | 江苏正大天晴药业股份有限公司 | 治心脑血管病的赤芍总苷组合物的制备方法 |
-
2004
- 2004-11-19 CN CNB2004100911379A patent/CN100411653C/zh active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102973676A (zh) * | 2012-12-14 | 2013-03-20 | 中国中医科学院西苑医院 | 一种防治心血管疾病的药物及其制备方法 |
CN102973676B (zh) * | 2012-12-14 | 2014-10-15 | 中国中医科学院西苑医院 | 一种防治心血管疾病的药物及其制备方法 |
CN103263486A (zh) * | 2013-06-13 | 2013-08-28 | 陈曦 | 一种具有降糖活性的赤芍提取物的应用 |
CN104337884A (zh) * | 2013-08-06 | 2015-02-11 | 颜明 | 一种预防和/或治疗糖尿病及其并发症的药物组合物 |
CN105232641A (zh) * | 2015-10-21 | 2016-01-13 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 赤芍总苷在制备预防或治疗微波辐射致神经细胞损伤药物中的用途、药物组合物及食品 |
CN105232641B (zh) * | 2015-10-21 | 2019-10-25 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 赤芍总苷在制备预防或治疗微波辐射致神经细胞损伤药物中的用途及药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN100411653C (zh) | 2008-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1754541A (zh) | 甾体皂苷药物组合物及其制备方法和用途 | |
CN1895408A (zh) | 防风通圣软胶囊及制备方法与质量控制方法 | |
CN1462620A (zh) | 灯盏细辛酚及其制备方法和在制药中的应用 | |
CN100506259C (zh) | 一种治疗糖尿病的药物组合物及其制备方法 | |
CN100534508C (zh) | 一种制备菝葜有效部位群的方法 | |
CN1876018A (zh) | 一种植物提取物和它的制备方法及用途 | |
CN1733054A (zh) | 一种山茱萸提取物及其制备工艺 | |
CN1895462A (zh) | 一种治疗前列腺炎的男康软胶囊 | |
CN101301374A (zh) | 一种枇杷叶总黄酮的制备方法及其降血糖和降血脂功能 | |
CN1778355A (zh) | 一种治疗糖尿病的中药组合物及其制剂和用途 | |
CN102579530A (zh) | 具有抗糖尿病作用的太白楤木总皂苷的制备方法及药物 | |
CN1923263A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN103006781B (zh) | 一种具有保肝作用的傣药复合提取物及其制备方法 | |
CN103432420B (zh) | 一种治疗糖尿病的中药组合物及其制备方法和检测方法 | |
CN1762359A (zh) | 乌药生物碱及其制备方法与在制药中的应用 | |
CN1823943A (zh) | 一种中药脑得生浓缩丸的制备工艺 | |
CN1369306A (zh) | 化橘红制剂及其生产方法 | |
CN101422522B (zh) | 一种中药制剂的制备方法 | |
CN101045077A (zh) | 一种胡芦巴口服固体制剂的制备方法及其应用 | |
CN1181836C (zh) | 一种治疗糖尿病的中药组合物 | |
CN105878337A (zh) | 一种抗糖尿病药用植物提取物的制备方法及其在制药和保健品中的应用 | |
CN1887309B (zh) | 一种防治骨质疏松及抑郁症的丹参有效部位群提取工艺 | |
CN1539844A (zh) | 降血脂药用2,3,5,4'-四羟基二苯乙烯-2-O-β-D-葡萄糖苷 | |
CN1605357A (zh) | 胡芦巴提取物及其制备方法和应用 | |
CN1431221A (zh) | 黄花倒水莲总皂苷及其药物组合物与制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIDA SHIJIA TECHNOLOGY DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: ZHOU YAWEI Effective date: 20150114 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150114 Address after: 100084 No. 123 North Main Street, Haidian District, Beijing, Zhongguancun Patentee after: Beida Shijia Technology Development Co. Ltd. Address before: 100084, Beijing, Zhongguancun, Haidian District North 123 Avenue, branch office incubator room 2206 Patentee before: Zhou Yawei |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 102206, 20 floor, No. 6, life road, Beijing, Changping District, 3 Patentee after: Beida Shijia Technology Development Co. Ltd. Address before: 100084 No. 123 North Main Street, Haidian District, Beijing, Zhongguancun Patentee before: Beida Shijia Technology Development Co. Ltd. |